Related by context. All words. (Click for frequent words.) 68 APOPTONE 64 Apoptone 63 Triolex 62 preclinical efficacy 62 TRIOLEX 62 PEG SN# 61 CCX# 61 MEK inhibitor 61 PSN# [002] 61 Sym# 61 Guanilib 61 vascular disrupting agent 61 ENMD # 61 vidofludimus 60 HQK 60 TBC# 60 OXi# 60 CBLC# 60 antiangiogenic activity 60 radiation sensitizer 59 proteasome inhibitor 59 XmAb# 59 ISIS # 59 Symadex 59 preclinically 59 nanoviricides 59 NEUMUNE 59 PD LID 59 Azedra 59 R#/MEM # 59 INCB# [001] 59 Tarvacin 59 PXD# 59 orally bioavailable 59 TRX# 58 NEUGENE 58 mGluR2 NAM 58 selective androgen receptor modulator 58 EndoTAG TM -1 58 R roscovitine 58 GRNCM1 58 Traficet EN 58 tanespimycin 58 ganetespib 58 TRIOLEX TM HE# 58 OMP #M# 58 Asentar 58 metaglidasen 58 GAP #B# 58 RDEA# 58 rFIXFc 58 phosphatidylserine PS targeting 58 neuroprotective properties 58 PDE4 inhibitor 58 depsipeptide 58 favorable pharmacokinetic profile 58 potent inhibition 58 epothilone 58 SPC# [001] 57 MAP# 57 DXL# 57 TG# [003] 57 CG# [003] 57 #ME# 57 CYC# 57 ALN TTR 57 Archexin 57 preclinical 57 milatuzumab 57 ALN VSP 57 INCB# [002] 57 BiTE antibody 57 PS# [001] 57 pomalidomide 57 targeting CD# 57 pertuzumab 57 CORT # 57 mitotic kinesins 57 Trofex 57 VitiGam 57 JAK1 57 CGEN # 57 anti amnesic 57 MEK inhibitor RDEA# 57 humanized anti 57 Mipomersen 57 Pimavanserin 57 Bruton tyrosine kinase Btk 57 anticancer agent 57 OncoVEX GM CSF 57 XL# [003] 57 S/GSK# 57 MEK inhibitors 57 NU# [001] 57 solithromycin 57 iroxanadine 57 highly selective endothelin 56 Tarvacin TM 56 GFT# 56 GAMMAGARD 56 CEQ# 56 PRTX 56 HuMax CD# 56 liposomal formulation 56 nonclinical studies 56 OHR/AVR# 56 GRN#L 56 Tyrima 56 mRNA antagonists 56 MB# [004] 56 BZL# 56 PSMA ADC 56 anti angiogenic 56 ApoB SNALP 56 mertansine 56 CA4P 56 corticosteroid dexamethasone 56 5 HT2C receptor 56 anti CD3 56 pharmacodynamic properties 56 CDK inhibitor 56 cannabinor 56 RhuDex ® 56 androgen independent 56 ImmunoVEX HSV2 56 Carfilzomib 56 cMET 56 immunomodulator 56 phase IIa clinical 56 systemically administered 56 preclinical studies 56 biodistribution 56 pretargeting 56 SparVax TM 56 protein kinase inhibitor 56 ATL# [001] 56 NGX# 56 mTOR inhibitors 56 MAb 56 AEG# 56 vascular disrupting 56 antisense inhibition 56 romidepsin novel 56 Azedra TM 56 oral bioavailability 56 JAK inhibitors 56 GLYX 56 Homspera 56 AACR NCI EORTC 56 HuMax EGFr 56 vascular disrupting agents 56 bexarotene 56 Phase Ib study 56 EOquin TM 56 CCR5 antagonist 56 TRO# 56 PCK# 56 Panzem 56 volociximab 56 GPR# agonist 56 Vidofludimus 56 Phase 1a clinical 56 vivo efficacy 56 VA# [002] 55 ANAVEX #-# [003] 55 vivo potency 55 Onconase 55 rBChE 55 Phase 2a trial 55 Solazed TM 55 selective kinase inhibitor 55 Serdaxin 55 mitogen activated ERK kinase 55 PRLX # 55 indibulin 55 antiviral potency 55 EZN 55 ALK inhibitor 55 CTAP# Capsules 55 Thiarabine 55 generation purine nucleoside 55 SRT# [003] 55 imatinib Gleevec ® 55 crizotinib PF # 55 antitumor 55 PRT# 55 MLN# 55 chemokine receptor 55 PEGPH# 55 GRNVAC1 55 humanized monoclonal antibody 55 AP# [003] 55 PROSTVAC TM 55 IMGN# 55 AKT inhibitor 55 Virulizin ® 55 mouse xenograft models 55 Anticalin ® 55 YONDELIS 55 HCV protease inhibitor 55 SERMs 55 vivo preclinical 55 Phase Ib clinical 55 RP# [002] 55 KNS # 55 selective modulator 55 enzastaurin 55 anti fibrotic 55 Aplidin R 55 IFN beta 55 TNFa 55 Alzhemed TM 55 laquinimod 55 LT NS# 55 TLR7 55 novel anticancer 55 urocortin 2 55 oral prodrug 55 TLR antagonists 55 selective inhibition 55 Factor VIIa 55 potent suppressor 55 SUVN 55 Vitaxin 55 iSONEP 55 HGS ETR2 55 blinatumomab 55 pharmacodynamic 55 tumor xenograft models 55 preclinical models 55 masitinib 55 radiolabeled 55 pharmacodynamic profile 55 Kahalalide F 55 Atiprimod 55 TACI Ig 55 Eg5 55 Panzem R 55 IAP inhibitor 54 DG# [001] 54 histone deacetylase inhibitor 54 HGS ETR1 54 seliciclib CYC# 54 demonstrated antitumor activity 54 miR #a [002] 54 antiangiogenic agents 54 pan HDAC inhibitor 54 CCR2 54 potent anticancer 54 CD# CEA 54 obatoclax 54 rhIL 7 54 tafamidis 54 orally dosed 54 peptide antigens 54 TKM ApoB 54 transfected cells 54 potent inhibitor 54 HuMax CD4 54 otelixizumab 54 beta HSD1 54 alvespimycin 54 forodesine 54 Angiolix 54 cardioprotective effects 54 BiTE 54 HCV protease 54 renin inhibitors 54 antiapoptotic 54 IL #E 54 CR# vcMMAE 54 Hsp# inhibitor 54 vivo validation 54 MET amplification 54 Aplidin 54 Protectan CBLB# 54 Radezolid 54 Valortim 54 drug GLPG# 54 MGCD# [001] 54 CYT# 54 ALN TTR# 54 MAXY G# 54 Xanafide 54 HCD# [002] 54 JAK3 54 TRIOLEX ™ 54 XL# XL# XL# 54 Tezampanel 54 Interferon alpha 54 selective agonist 54 JAK2 inhibitors 54 atacicept 54 ESBA# 54 CD# antibody [001] 54 uricase 54 huC# DM4 54 CRLX# 54 ATL# [002] 54 DOS# 54 thymalfasin 54 MYDICAR 54 somatostatin analogue 54 TAT# 54 IMA# 54 RGB # 54 thrombin receptor 54 Hsp# Inhibitor 54 Cytolin R 54 xenograft models 54 novel prodrug 54 axitinib 54 GHRH 54 LymphoStat B 54 Hsp# inhibition 54 LHRH antagonist 54 Cloretazine R VNP#M 54 TAKSTA 54 Safinamide 54 JAK2 inhibitor 54 inhibit metastasis 54 bortezomib Velcade 54 humanized monoclonal antibodies 54 synthetic siRNA 54 immune modulatory 54 Aurexis 54 IFN alpha 54 RNAi therapeutic targeting PCSK9 54 nucleotide analog 54 ostarine 54 XL# XL# 54 Ophena TM 54 interferon IFN 54 BiTE antibodies 54 Synavive 54 cediranib 54 Plicera 54 Zybrestat 54 RenaZorb TM 54 retapamulin 54 vitro experiments 54 ularitide 54 OvaRex ® MAb 54 Panzem R NCD 54 triphendiol 54 dacetuzumab 54 Anticalin R 54 Valortim ® 54 Blinatumomab 54 Thiovir 54 ENMD 54 KSP inhibitors 54 AEOL # 54 IMP# 54 randomized discontinuation trial 54 CoFactor 54 CCR9 antagonist 54 polymerase inhibitor 54 HuLuc# 54 NEUVENGE 54 BCX# 54 perifosine 54 neuroprotective 54 Anavex #-# 54 Trofex TM 54 resolvin 54 PRX # 54 Debio 54 Bezielle 54 angiogenesis inhibitor 54 pharmacokinetic properties 53 Curaxin 53 DACH platinum 53 Aflibercept 53 PNP inhibitor 53 perifosine KRX 53 dexpramipexole 53 Dapagliflozin 53 antitumoral 53 pDCs 53 Multimeric 53 Curaxin CBLC# 53 hGH CTP 53 teriflunomide 53 5 HT3 receptor 53 TRC# 53 chemopreventive agent 53 RLY# 53 CDK inhibitors 53 GV# [001] 53 H#N# VLP vaccine 53 antisense oligonucleotide 53 rNAPc2 53 nucleoside analog 53 tyrosine phosphorylation 53 Darinaparsin 53 anticancer activity 53 SIRT2 53 murine models 53 Glufosfamide 53 ZYBRESTAT 53 Aurora kinase 53 Fx #A 53 antitumor activity 53 bardoxolone methyl 53 Kevetrin 53 CD3 monoclonal antibody 53 ARIKACE ™ 53 fosbretabulin 53 lupus nephritis 53 Bendavia 53 anti CD3 monoclonal 53 anticancer compound 53 trodusquemine 53 INT# [002] 53 Dasatinib 53 CK # 53 Nanobody 53 Telintra 53 OvaRex R 53 ErbB3 HER3 53 molecularly targeted 53 Menerba 53 ThGRF 53 resolvins 53 NN# [001] 53 radezolid 53 induces apoptosis 53 nitric oxide donating prostaglandin 53 Pharmacokinetic analyzes 53 tarenflurbil 53 GPR# [002] 53 Phenoptin 53 protein tyrosine phosphatase 53 Preclinical studies 53 MAGE A3 ASCI 53 PLX cells 53 trabectedin 53 IL 1beta 53 AMN# [001] 53 therapeutic monoclonal antibody 53 adecatumumab 53 ANAVEX #-# [001] 53 PI3K/Akt pathway inhibitor 53 gallium containing 53 transgene expression 53 targeting PCSK9 53 CaPre TM 53 protein tyrosine phosphatase 1B 53 pharmacodynamic markers 53 antisense inhibitors 53 ELND-#/AZD-# 53 Onalta ™ 53 Tarceva TM 53 delafloxacin 53 Ceflatonin 53 SAR# [004] 53 riociguat 53 Sphingomab 53 Amplimexon 53 MDV# 53 LPA1 receptor 53 elacytarabine 53 eniluracil 53 Posiphen 53 LY# [003] 53 AEZS 53 Voreloxin 53 Ceplene/IL-2 53 Elagolix 53 huN# DM1 53 Phase IIa trials 53 LY# [002] 53 Aurora Kinase 53 Lixivaptan 53 CUDC 53 veltuzumab 53 PRX# 53 novel VDA molecule 53 teplizumab 53 ENaC 53 MOR# 53 IFN α 53 velafermin 53 MYDICAR ® 53 MGd 53 BRAF kinase 53 novel synthetic peptide 53 DAVANAT 53 splice variant 53 cobiprostone 53 RAV# 53 somatostatin 53 Imprime PGG 53 AVN# [001] 53 rHuPH# 53 generation antisense 53 hypoxia inducible factor 53 antitumor efficacy 53 siRNA therapeutic 53 JAK2 53 KSP inhibitor 53 oral JAK1 53 synthetic peptide 53 XmAb 53 Annamycin 53 antitumor effects 52 oral picoplatin 52 humanized antibody 52 HCV protease inhibitors 52 Bortezomib 52 Targretin 52 SLx 52 Protelos R 52 Muraglitazar 52 nucleoside 52 Valortim R 52 Neuradiab 52 ICA # 52 Oral NKTR 52 multitargeted 52 ongoing Phase 1b 52 BAY #-# 52 Ostarine 52 maximally tolerated dose 52 INCB# [003] 52 OncoVEX 52 Phase IIa clinical 52 oral FTY# 52 pharmacokinetics PK 52 Amrubicin 52 ON #.Na 52 ProLindac 52 EGS# 52 satraplatin Phase 52 Marqibo 52 BRIM2 52 TH# [003] 52 cancer immunotherapies 52 Phase 2a clinical 52 anticoagulant reversing agent 52 tezampanel 52 farletuzumab 52 samalizumab 52 mapatumumab 52 Chemophase 52 EGFR HER2 52 Onalta 52 Phase 1b clinical trials 52 CCR9 52 CB# [002] 52 induce apoptosis 52 NXL# 52 AQ4N 52 PEG Interferon lambda 52 elotuzumab 52 HspE7 52 tiapamil 52 experimental autoimmune encephalomyelitis 52 Vicriviroc 52 Vectibix monotherapy 52 vivo 52 investigational humanized monoclonal antibody 52 Pharmacokinetic studies 52 talabostat 52 PEGylated interferon beta 1a 52 prostate carcinoma 52 HuCAL antibodies 52 decitabine 52 NEUGENE antisense 52 HSP# inhibitor 52 orally administered inhibitor 52 Phase IIB 52 DB# [003] 52 nalbuphine ER 52 RNAi therapeutic targeting 52 Vaxfectin 52 UPLYSO 52 MF# [002] 52 PrevOnco ™ 52 DFMO 52 Cannabinor 52 ribonuclease 52 TELCYTA 52 pharmacokinetic PK profile 52 Dalbavancin 52 Corlux 52 Phase #/#a trial 52 TLR8 52 Radilex 52 Lpathomab 52 metastatic castration resistant 52 Vandetanib 52 Solazed 52 pharmacological chaperone 52 activin 52 non nucleoside HCV 52 EOquin 52 Deforolimus 52 Cloretazine ® 52 sapacitabine 52 Epratuzumab 52 SNALP technology 52 Temsirolimus 52 Phase #b/#a clinical 52 TLR8 agonist 52 sulodexide 52 trastuzumab emtansine T DM1 52 antisense drug 52 PLK1 SNALP 52 aurora kinase 52 PI3K/mTOR 52 bardoxolone 52 neratinib 52 Pralatrexate 52 immunomodulatory 52 Angiocept 52 Hedgehog pathway 52 potent antitumor activity 52 anti EGFR antibody 52 alpha TNF 52 GPx 52 Squalamine 52 immunomodulation 52 serine protease 52 proteasome inhibitors 52 GSK# [001] 52 anticancer therapeutics 52 Phase IIIb clinical 52 BRAF inhibitor 52 ONCONASE 52 palifosfamide 52 eprotirome 52 epratuzumab 52 nicotinic alpha 7 52 maturation inhibitor 52 NOD mouse 52 glycosylated 52 dose escalation Phase 52 mineralocorticoid receptor 51 FLT3 51 anti leukemic 51 Phase Ia 51 registrational trial 51 plasma kallikrein 51 sunitinib malate 51 sPLA2 51 nucleoside analogue 51 tubulin inhibitor 51 PEGylated 51 antiangiogenic therapy 51 seliciclib 51 ritonavir boosting 51 LNP formulations 51 sodium glucose cotransporter 51 TLR9 agonist 51 xenograft model 51 gamma secretase inhibitor 51 oral gallium 51 ASONEP 51 trastuzumab DM1 T DM1 51 targeted radiotherapeutic 51 teduglutide 51 CB2 selective receptor agonist 51 pharmacodynamic PD 51 GALNS 51 darinaparsin ZIO 51 TNFalpha 51 transgenic mouse models 51 glucagon receptor 51 VLP vaccine 51 #I TM# 51 viral kinetics 51 torezolid phosphate 51 CLORETAZINE TM VNP#M 51 epigenetic therapies 51 cytokine interleukin 51 GLP toxicology studies 51 Locteron 51 preclinical pharmacokinetic 51 adenoviral 51 brivaracetam 51 ProSavin 51 siRNA mediated 51 platinum chemotherapeutic 51 Daclizumab 51 tesetaxel 51 pegylated liposomal doxorubicin 51 bevirimat 51 TPI ASM8 51 KB# [002] 51 cathepsin K inhibitor 51 tumor antigen 51 EP #R 51 AEGR 51 modulator SERM 51 dosing cohort 51 antisense drugs 51 small molecule activators 51 RH1 51 receptor antagonists 51 TREANDA 51 TMC# [002] 51 PBT2 51 flavopiridol 51 BNC# 51 syngeneic 51 polymerase inhibitors 51 histone deacetylase HDAC 51 next generation URAT1 51 rhIGFBP 3 51 humanized monoclonal 51 entinostat 51 Canvaxin TM 51 SNT MC# 51 TNF Tumor Necrosis Factor 51 ixabepilone 51 Clusterin 51 insulin sensitizers 51 CYT# potent vascular disrupting 51 Hedgehog signaling pathway 51 IRX 2 51 cilengitide 51 enzyme cofactor 51 ARIKACE 51 PANVAC VF 51 Androxal TM 51 VEGF Trap 51 Quinamed 51 PEGylated anti 51 CINTREDEKIN BESUDOTOX 51 tolevamer 51 Golimumab 51 pharmacokinetic 51 HIV integrase inhibitors 51 Prodarsan ® 51 FGFR 51 Phase #b/#a trial 51 TRV# [001] 51 phase Ib 51 tyrosine kinase inhibitor 51 oral proteasome inhibitor 51 castration resistant prostate cancer 51 preclinical compounds 51 selective androgen receptor modulators 51 Perifosine 51 muscarinic 51 elesclomol 51 JAK inhibitor 51 IIa trial 51 gemcitabine Gemzar ® 51 pharmacokinetic PK 51 immunoglobulin Ig 51 Preclinical studies suggest 51 lomitapide 51 cetuximab Erbitux ® 51 glucokinase activator 51 ARX# [001] 51 Talabostat 51 YONDELIS R 51 preclinical toxicology 51 Elesclomol 51 selective agonists 51 proteasome inhibitor bortezomib 51 PTP 1B 51 Aeroquin 51 IFN gamma 51 PHD2 51 TÎ ² 4 51 PN# [001] 51 therapeutic monoclonal antibodies 51 inhibitor RG# 51 omega interferon 51 generation URAT1 inhibitor 51 galiximab 51 potently inhibited 51 Azedra ™ 51 BN# [002] 51 FluCide 51 Phase 2b trial 51 signal transduction inhibitor 51 apremilast 51 CBLB# 51 leukemia AML 51 dyskinesia PD LID 51 ruxolitinib 51 anti proliferative 51 Ofatumumab 51 UVIDEM 51 immunoregulation 51 SGX# 51 bortezomib Velcade ® 51 PROCHYMAL 51 GSK # 51 Phase IIa trial 51 novel peptide 51 telomerase inhibitor 51 Hsp# inhibitors 51 Protexia R 51 erythropoietic 51 mTOR inhibitor 51 Everolimus 51 dose cohort 51 ERK activation 51 Protexia ® 51 bispecific antibody 51 investigational immunotherapy 51 IDX# 51 renin inhibitor 51 virus HCV protease inhibitor 51 ATL/TV# 51 dose escalation clinical 51 C5a 51 histone deacetylase HDAC inhibitor 51 personalized immunotherapy 51 GKAs 51 optimal dosing regimens 51 evaluating tivozanib 51 A1PI 51 hematological malignancies 51 Chrysalin 51 nitazoxanide 51 alpha#beta# integrin 51 initiate Phase 1b 51 davunetide intranasal AL 51 anti angiogenic agent 51 hypoxia selective 51 isoform selective 51 potently inhibit 51 CXB# 51 administered subcutaneously 51 INGN 51 MAP kinase 51 siRNAs targeting 51 novel topoisomerase 51 Exherin TM 51 PF # [001] 51 Phase 1b clinical 51 gonadotropin releasing hormone GnRH 51 tranilast 51 TNF α 51 PDE# inhibitors 51 phase IIb 51 telomerase therapeutic 51 TELINTRA 51 Tumor Necrosis Factor 51 SAR# [002] 51 Phase IIb clinical 51 imetelstat 51 ELACYT 51 TLR9 51 Ambrisentan 51 antiviral activity 51 NKTR 51 immunoregulatory 51 Immunohistochemical analysis 51 AV HALT 50 Rasagiline 50 phase IIa 50 SMT C# 50 Enzastaurin 50 Marqibo TM 50 SGLT2 50 CTA# Injection 50 ataluren 50 Seliciclib 50 APD# 50 ghrelin receptor 50 oral antiviral 50 Nanobodies 50 GDIR 50 MORAb 50 neutralizing antibody 50 antibody MAb 50 osteoblast 50 Acapodene 50 rFVIIIFc 50 immunomodulatory therapy 50 ALN RSV# 50 XYOTAX TM 50 Nektar proprietary 50 somatostatin receptor 50 posaconazole 50 bispecific 50 neuroprotectant 50 Afatinib 50 Vaxfectin R 50 interleukin IL 50 ALN PCS 50 2DG 50 incyclinide 50 HDAC inhibitor 50 Akt activation 50 C#BL 6 mice 50 Reolysin 50 5 HT4 receptor 50 etanercept Enbrel 50 HGS# 50 gefitinib Iressa 50 CD#c 50 Altastaph 50 registrational 50 NTx TM -# 50 CD# monoclonal antibody 50 immune stimulatory 50 ibudilast 50 Pertuzumab 50 zanolimumab 50 Phase 1b trial 50 peroxisome proliferator activated 50 UCP2 50 siRNA therapeutics 50 MYCN 50 tolerability profiles 50 PI3K delta 50 Elotuzumab 50 leading oral taxane 50 bazedoxifene 50 nanomolar 50 TLK# 50 DEB# 50 cyclin dependent kinase inhibitor 50 tyrosine kinase inhibitors 50 AZD# 50 Neo Kidney Augment 50 Boceprevir 50 Genz # 50 Darusentan 50 novel histone deacetylase 50 antifibrotic 50 anticancer compounds 50 JAK#/JAK# 50 PARP inhibitors 50 midstage clinical 50 Cloretazine VNP#M 50 SGS# 50 EndoTAG TM 50 affinity antibodies 50 punctal plug 50 menadione 50 iniparib 50 ILLUMINATE 50 pegylated 50 SARMs 50 calcitonin 50 #beta HSD1 50 multiple ascending dose 50 metastatic RCC 50 Myocet 50 epothilones 50 NNRTIs 50 paclitaxel Taxol ® 50 receptor blocker 50 EGFR inhibitors 50 eculizumab 50 omecamtiv mecarbil 50 HDACi 50 Opexa 50 Relivar 50 IGFBP2 50 Alocrest 50 potent inhibitors 50 immunogenicity 50 investigational monoclonal antibody 50 Tamibarotene 50 brostallicin 50 rxRNA 50 lumiliximab 50 BAL# [002] 50 alpha7 NNR 50 HuR 50 CRAC channel 50 Maxy G# 50 drug conjugate 50 Zolinza 50 anti angiogenic drugs 50 Phase #b/#a 50 reslizumab 50 IL 1ß 50 XOMA 3AB 50 Alpharadin 50 AMD# [003] 50 beta1 50 bendamustine 50 BioVant 50 BrachySil 50 ADAGIO study 50 Phase IIb trials 50 Genasense ® oblimersen 50 ATryn R 50 ERb 50 CRTH2 50 Spiegelmer ® 50 pharmacokinetic profile 50 XL# anticancer compounds 50 NP2 Enkephalin 50 ADX# 50 ISTODAX 50 TRPV3